Emergent Biosolutions Inc. Capital expenditures

Capital expenditures of EBS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital expenditures growth rates and interactive chart. Capital expenditures, commonly known as Capex, are funds used by a company to acquire, upgrade, and maintain physical or intangible assets such as property, buildings, an industrial plant, technology, software or equipment. Capex is often used to undertake new projects or investments by the firm. A company must invest over its lifetime into productive assets to maintain its competitiveness and ensure its survival.

Highlights and Quick Summary

  • Capital expenditures for the quarter ending June 30, 2023 was $-12.5 Million (a -17.22% decrease compared to previous quarter)
  • Year-over-year quarterly Capital expenditures decreased by -55.2%
  • Annual Capital expenditures for 2022 was $-116 Million (a -48.53% decrease from previous year)
  • Annual Capital expenditures for 2021 was $-225 Million (a 59.57% increase from previous year)
  • Annual Capital expenditures for 2020 was $-141 Million (a 62.26% increase from previous year)
  • Twelve month Capital expenditures ending June 30, 2023 was $-79.1 Million (a -19.86% decrease compared to previous quarter)
  • Twelve month trailing Capital expenditures decreased by -43.05% year-over-year
Trailing Capital expenditures for the last four month:
30 Jun '23 31 Mar '23 31 Dec '22 30 Sep '22
$-79.1 Million $-98.7 Million $-116 Million $-139 Million
Visit stockrow.com/EBS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital expenditures of Emergent Biosolutions Inc.

Most recent Capital expendituresof EBS including historical data for past 10 years.

Interactive Chart of Capital expenditures of Emergent Biosolutions Inc.

Emergent Biosolutions Inc. Capital expenditures for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2023 $-12.5 $-15.1 – – –
2022 $-23.6 $-27.9 $-32.1 $-32.2 $-115.8
2021 $-46.7 $-55.2 $-67.0 $-56.1 $-225.0
2020 $-36.0 $-45.7 $-35.1 $-24.2 $-141.0
2019 $-36.1 $-15.3 $-14.1 $-21.4 $-86.9
2018 $-20.8 $-26.1 $-11.0 $-11.6 $-69.5
2017 $-12.42 $-12.78 $-9.3 $-20.3 $-54.8
2016 $-19.96 $-17.0 $-21.03 $-18.21 $-76.2
2015 $-11.18 $-13.95 $-10.6 $-9.08 $-44.81
2014 $-16.05 $-5.22 $-4.81 $-4.59 $-30.67
2013 $-7.6 $-20.3 $-6.44 $-7.68 $-42.02
2012 $-12.9 – – – $-42.08

Business Profile of Emergent Biosolutions Inc.

Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic
© stockrow.com